

# EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

NCT07438067

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Daihong Liu
Enrollment	18 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- The patient must be aged 18-75 years.
- Must have undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT).
- Must have EBV-DNA viremia post-transplant, with EBV-DNA  $\geq 1000$  copies/mL (on two consecutive tests or one test  $\geq 10,000$  copies/mL).
- Karnofsky Performance Score (KPS) of 70 or higher.
- Expected survival of at least 3 months.
- ... and 2 more (see full listing online)

### Exclusion (7)

- Active GVHD (Grade 2 or higher) or requiring  $\geq 0.5$  mg/kg/day corticosteroids for GVHD.
- History of CMV viremia or disease within the past week.
- PTLD (Post-Transplant Lymphoproliferative Disorder) diagnosed or suspected within 1 week before infusion.
- Severe active infections (excluding EBV and CMV).
- Serious allergic reactions or contraindications to the infusion.
- ... and 2 more (see full listing online)

## Locations (1 total)

---

Chinese PLA General Hospital, Beijing, China